论文部分内容阅读
目的:探讨乌司他丁对急性心衰患者血管内皮功能和血清半乳凝素的影响。方法:选择2013年4月至2015年11月在我院治疗的急性心衰患者58例,根据随机数字表法分为对照组及观察组,各29例。两组患者均采取常规治疗,观察组患者在此基础上以乌司他丁治疗,观察两组患者的血管内皮功能、血清半乳素-3及NT-pro BNP水平。结果:与治疗前相比,两组患者治疗后的LVEF、CO均明显升高,差异显著(P<0.05)。与对照组相比,观察组治疗后LVEF、CO均显著更高,差异显著(P<0.05)。与治疗前相比,两组患者的肱动脉FMD明显升高,差异显著(t=3.063、24.469,P<0.05)。与对照组相比,观察组治疗后肱动脉FMD明显更高,差异显著(t=15.561,P<0.05)。两组患者治疗前的Gal-3及NT-pro BNP对比后,差异无统计学意义(P>0.05)。与治疗前相比,两组患者的Gal-3及NT-pro BNP明显更低,差异有统计学意义(P<0.05)。与对照组相比,观察组治疗后的Gal-3、NT-pro BNP水平显著更低(P<0.05)。结论:乌司他丁对急性心衰有确切临床疗效,可显著急性心衰患者血管内皮功能,降低患者血清半乳凝素-3含量。
Objective: To investigate the effect of ulinastatin on vascular endothelial function and serum galectin in patients with acute heart failure. Methods: Fifty-eight patients with acute heart failure who were treated in our hospital from April 2013 to November 2015 were divided into control group and observation group according to random number table. The patients in both groups were treated routinely. The patients in the observation group were treated with ulinastatin, and the vascular endothelial function, serum prolactin-3 and NT-pro BNP levels were observed in both groups. Results: Compared with those before treatment, LVEF and CO in both groups were significantly increased after treatment (P <0.05). Compared with the control group, LVEF and CO in the observation group after treatment were significantly higher, the difference was significant (P <0.05). Compared with before treatment, FMD of brachial artery in both groups were significantly increased (t = 3.063,24.469, P <0.05). Compared with the control group, the FMD of the brachial artery in the observation group was significantly higher (t = 15.561, P <0.05). The difference of Gal-3 and NT-pro BNP between the two groups before treatment was not statistically significant (P> 0.05). Compared with before treatment, the two groups of patients with Gal-3 and NT-pro BNP was significantly lower, the difference was statistically significant (P <0.05). Compared with the control group, the levels of Gal-3 and NT-pro BNP in the observation group were significantly lower (P <0.05). Conclusion: Ulinastatin has definite clinical curative effect on acute heart failure, and can significantly improve the vascular endothelial function in patients with acute heart failure and decrease the serum galectin-3 level.